Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

97.07EUR
9:22am EDT
Price Change (% chg)

€0.24 (+0.25%)
Prev Close
€96.83
Open
€97.50
Day's High
€98.47
Day's Low
€96.87
Volume
795,997
Avg. Vol
2,114,914
52-wk High
€104.35
52-wk Low
€77.53

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a German management holding company with core competencies in the field of health care, nutrition and high-tech materials. It's business operations are organized into three subgroups: HealthCare, involved in the research, development and manufacture of health products for people and animals, CropScience, engaged in... (more)

Overall

Beta: 0.94
Market Cap (Mil.): €80,073.36
Shares Outstanding (Mil.): 826.95
Dividend: 2.10
Yield (%): 2.17

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 25.11 33.36 33.52
EPS (TTM): 3.86 -- --
ROI: 8.46 19.69 18.94
ROE: 16.28 20.38 19.71
Search Stocks

BRIEF-Bayer seeks approval of Riociguat in Japan

FRANKFURT, April 23 - Bayer AG : * Says submits application for approval of riociguat to treat pulmonary

23 Apr 2014

Boehringer 2013 profit up on Pradaxa sales, cost cuts

INGELHEIM, Germany - German drugmaker Boehringer Ingelheim's operating income rose 14 percent last year as cost cuts and sales of anti-blood-clotting drug Pradaxa helped counter the impact of currency effects, it said on Tuesday.

15 Apr 2014

BRIEF-Bayer initiates two phase III trials with rivaroxaban in medically-ill patients and children at high risk of blood clots

FRANKFURT, March 31 - Bayer AG : * Says initiates two phase III trials with Rivaroxaban in medically-ill

31 Mar 2014

CORRECTED-Bayer receives EU nod for lung drug Adempas

(Corrects to show Adempas approved for first time in Europe, not for wider use, in headline and first paragraph)

31 Mar 2014

Bayer gets EU nod to widen use of lung drug Adempas

FRANKFURT - German drugmaker Bayer said on Monday it won approval in the European Union to widen the use of lung drug Adempas to two life-threatening forms of pulmonary hypertension.

31 Mar 2014

BRIEF-Bayer sells patents for carbon nanotubes and graphenes

FRANKFURT, March 31 - Bayer AG : * Says sells patents for carbon nanotubes and graphenes

31 Mar 2014

Bayer to invest 100 mln euros in Beijing plant

FRANKFURT, March 28 - Bayer said its healthcare business would invest around 100 million euros ($137 million) to significantly boost production capacity at its plant in Beijing.

28 Mar 2014

European shares fall back as Crimea, China PMI weigh

* China's lower-than-expected PMI weighs on sentiment (Adds closing prices with no other changes to text)

24 Mar 2014

European shares fall back as Crimea, China PMI weigh

* China's lower-than-expected PMI weighs on sentiment (Adds quote, details, updates prices)

24 Mar 2014

European shares dip early as China data weighs

* FTSEurofirst 300 down 0.4 pct, Euro STOXX 50 down 0.3 pct

24 Mar 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks